Articles by Meso Foundation

Community, Friendship Through Fundraising For Mesothelioma

Throughout February, we posted blogs about how to host your own fundraising event, the importance of event sponsors, and how to sustain your audience. We’re continuing this series of fundraising posts with a blog by Jill Waite, a Fundraise for Meso event planner, on how fundraising has impacted her life:
Five years ago, I was determined […]


How Many Fake “Friends” Do You Have on Facebook?

by Maja Belamaric, Director of Communications, Mesothelioma Applied Research Foundation
A few months ago, I logged into my Facebook account as I always do first thing in the morning. While I usually receive only a few random friend requests here and there, that morning I woke up to several just overnight.
After a few minutes of clicking […]


Registration Opens for our Multi-City Mesothelioma Symposium

You can now register to attend the Meso Foundation’s 2016 International Symposium on Malignant Mesothelioma in Houston, San Francisco, and Chicago.
We understand that for many mesothelioma patients and their families, travel can be difficult, and attending a conference at the other end of the country may be prohibitive. With that in mind, we decided to […]


Best Wishes to Verastem in their New Endeavors in Cancer Research

Just today, we learned that Verastem, a biotech company that has previously done research in mesothelioma, has now embarked on several new projects.
In the news, announced in a press release, the company lists several projects, including this one:
Clinical Collaboration with Pfizer and Merck KGaA to Evaluate Combination of VS-6063 and Avelumab in Ovarian Cancer –In March […]


Despite Negative Results, Meso Foundation Grateful for Investment Into Disease

The Meso Foundation released a statement from its executive director, Mary Hesdorffer, APRN, about AstraZeneca’s tremelimumab trial for mesothelioma.
In an AstraZeneca press release issued yesterday, the company states that “DETERMINE, the Phase IIb clinical trial of 10 mg/kg tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint […]